Open Access Highly Accessed Pre-publication history

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Dimitrios Pectasides*, George Papaxoinis, Konstantine T Kalogeras, Anastasia G Eleftheraki, Ioannis Xanthakis, Thomas Makatsoris, Epaminondas Samantas, Ioannis Varthalitis, Pavlos Papakostas, Nikitas Nikitas, Christos N Papandreou, George Pentheroudakis, Eleni Timotheadou, Angelos Koutras, Joseph Sgouros, Dimitrios Bafaloukos, George Klouvas, Theofanis Economopoulos, Konstantinos N Syrigos and George Fountzilas

BMC Cancer 2012, 12:271  doi:10.1186/1471-2407-12-271

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 Manuscript 04 Sep 2011
Reviewer's Report Lara Lipton 14 Jan 2012
Reviewer's Report Wei Chua 04 Apr 2012
Reviewer's Report Wei Chua 04 Apr 2012
Resubmission - Version 2 Manuscript Author's comment 06 May 2012
Editorial acceptance 16 May 2012
Published 29 Jun 2012